The Promise of Specialty Oncology Innovations in the Drug Pipeline

May 01, 2019


The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at Asembia's 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas.

Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer

April 12, 2019


The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.

Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics

March 07, 2019


Administration of immuno-oncology therapy for cancer diagnoses in the community clinic setting is associated with lower costs compared with administration in a hospital-based clinic setting.

This Week in Managed Care: February 15, 2019

February 15, 2019


This week, the top managed care news included increased demand for long-acting contraception since President Trump took office; a payer decision on an insulin pump alarmed diabetes advocates; and despite being involved in cancer treatment decisions, many primary care providers don't feel prepared to do so.

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

February 14, 2019


Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.

Is Immunotherapy the Future of Glioblastoma Treatment?

February 13, 2019


Immunotherapy has seen great success in the treatment of numerous cancers, from melanoma to lung, breast, colorectal, kidney, and even some brain cancers. But thus far, despite several attempts, the devastating brain disease glioblastoma has not been among the immunotherapy success stories. In fact, glioblastoma researchers have had few advances in more than a decade.

Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy

January 19, 2019


Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.

Ted Okon: A Different Reimbursement Approach Is Needed for CAR T, Other Innovative Therapies

December 27, 2018


As new, innovative therapies with high price tags, such as chimeric antigen receptor (CAR) T-cell therapy, come to market, the US health system will have to start looking at different approaches for reimbursement, said Ted Okon, MBA, executive director of the Community Oncology Alliance.

Pembrolizumab Superior to Standard of Care in SCC

December 26, 2018


A recent trial looked to compare the efficacy and safety of pembrolizumab (Keytruda) with the standard of care for the treatment of head and neck squamous cell carcinoma (SCC).

FDA Grants Accelerated Approval to Pembrolizumab for MCC

December 22, 2018


Earlier this week, the FDA granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).